



**Fig. S2. Intratumoral delivery of DC.IL32 promotes tumor infiltration by host myeloid DC.** Tumors were isolated from tumor-bearing mice treated as outlined in Fig. 5 and single cell digests analyzed for CD11c<sup>+</sup>CFSE<sup>neg</sup> host DC content (panel A) and for the subset of CD11c<sup>+</sup>CFSE<sup>neg</sup> cells expressing markers associated with myeloid (CD11b<sup>+</sup>), lymphoid (CD8α<sup>+</sup>) or plasmacytoid (B220<sup>+</sup>) lineage (panel B) by flow cytometry. Data are depicted in (mean ± SD) absolute numbers of cells bearing the indicated phenotype per gram of tumor tissue analyzed. **\*\***p < 0.05 versus DC.null or DC.ψ5 treatment groups.